Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.48 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.48 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.48 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD1 | P21728 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16977554 | 0.98 | TAAR1 (0.50) | TAAR1DRD2DRD1KDM4EADRA2A | |
| Hydrochloric Acid SCHEMBL6952555 | 0.96 | DRD2 (0.52) | TAAR1DRD2DRD1KDM4EADRA2A | |
| SCHEMBL9253968 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL25263373 | 0.79 | LOXL2 (0.55) | LOXL2 | |
| SCHEMBL13069799 | 0.78 | CNR1 (0.48) | KDM4EMAPK1RECQLLMNATSHR | |
| SCHEMBL5361827 | 0.76 | CAPN1 (0.43) | ALDH1A1LMNA | |
| SCHEMBL16583871 | 0.75 | LOXL2 (0.52) | TAAR1DRD2DRD1KDM4EADRA2A | |
| SCHEMBL4134209 | 0.75 | NOS3 (0.61) | TAAR1DRD2DRD1KDM4EADRA2A | |
| SCHEMBL29829781 | 0.74 | — | — | |
| SCHEMBL5109950 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090012060-A1 | Antitumor Agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012060-A1 | Antitumor Agent | NR1H3, NR1I3, NR0B1 | ADRA2A 2225/4885SLC6A2 4027/4885SLC6A3 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.